SNDX Q2 2025 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+984.5% YoY

Gross Profit

$37M96.6% margin

Operating Income

-$69M-182.7% margin

Net Income

-$72M-189.3% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

+89.4%

Cash Flow

Operating Cash Flow

-$88M

Free Cash Flow

-$88M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$596M

Total Liabilities

$439M

Stockholders' Equity

$157M

Cash & Equivalents

$109M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$4M	+984.5%
Gross Profit	$37M	$4M	+948.0%
Operating Income	-$69M	-$74M	+6.6%
Net Income	-$72M	-$68M	-5.6%

Revenue Segments

Product

$29M75%

Collaboration revenue

$9M25%